ClinicalTrials.gg
RecruitingNCT07246382ORANEATUpdated Oct 5, 2026

Evaluation of a Customizable Antibiotic Stewardship Program Tailored to French Nursing Homes

An interventional study of The ORANEAT program in Antibacterial Agents, sponsored by University of Lorraine. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Lorraine · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 5, 2026Now RecruitingFirst site in France+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To tackle antimicrobial resistance (AMR), i.e., one of the top 10 global health threats, antimicrobial stewardship (AMS) programs, i.e., coherent sets of actions promoting responsible use of antimicrobials, have been developed. Despite growing evidence about their effectiveness, their implementation remains suboptimal. Qualifying as complex interventions, these programs are prone to interactions with context, potentially compromising their successful transfer to other settings. AMR remains critical in French nursing homes (NHs). AMS programs have proven effective in reducing antimicrobial resistance in hospitals and in NHs. However, the evidence is inconsistent across studies in NHs and mostly based on North American and North European AMS programs and studies, raising concerns about transferability that might occur while implementing such AMS programs in French NHs. For instance, health systems and NH funding and organization vary considerably across countries, resulting in potential key determinants driving antibiotic use in such facilities in some countries that might remain untargeted by AMS programs developed in other countries. In addition, inconsistent effectiveness of AMS programs in NHs might also result from implementation issues, raising concerns about the strategies used to implement such programs. Based on extensive logic models linking psychosocial and organizational determinants driving antibiotic use in NHs of diverse countries, we developed and pilot-tested a customizable AMS program (i.e., the ORANEAT program) suited to French NHs, including three major components: (i) a contextual diagnostic regarding AMS in the targeted NH; (ii) based on the results of the contextual diagnostic, a bundle of tools selected from an AMS-toolkit including actions and tools suited to French NH setting; and (iii) implementation support relying on French structures involved in tackling AMR (i.e., CRAtb and CPias).

This study aims to assess the effectiveness, the sustainability, the implementation, and the transferability of the ORANEAT program in French NHs, using a mixed-method approach (quantitative and qualitative data). A cluster randomized controlled trial with two arms (ORANEAT program vs. no specific intervention) will be conducted; the cluster being the NH. The primary outcome to measure the effectiveness is total antibiotic use expressed in defined daily doses/1000 resident-days/month.

02

Conditions studied

  • Antibacterial Agents

Keywords

  • Antimicrobial Stewardship
  • Nursing Homes
03

In context

Lead sponsor

University of Lorraine is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Nursing homes

Inclusion criteria:

  • Nursing home located in one of the geographical areas participating in the study in two French regions (i.e., geographical areas covered by experts in antibiotic stewardship and/or in infection prevention and control who agreed to participate in the study)

Exclusion criteria:

  • Nursing home with a pharmacy for internal use
  • Participation to the pilot study
  • Data from the Health Insurance reimbursement database (Système national des données de santé) not available on the study period
  • Refusal of the nursing director to participate in the study (for Arm 1 only)

Residents (Outcomes 1 to 4 and outcome 12)

Inclusion criteria:

  • Resident aged 18 or more who had lived in one of the participating nursing homes during the study period.

Exclusion criteria:

/

Healthcare professionals (Outcomes 11, 13 and 15)

Inclusion criteria:

  • Healthcare professionals aged 18 or more working in one of the participating nursing homes from Arm 1 (including healthcare professionals who provide services to or collaborate with the nursing home even if they are not on-site, e.g., private general practitioners, community pharmacists, microbiologists, and professionals responsible for the implementation support).

Exclusion criteria:

  • Refusal to complete the self-administered questionnaires or to participate in qualitative investigations.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Nursing homes in the experimental group will receive the ORANEAT antibiotic stewardship program.

    Other: The ORANEAT program

  • No intervention
    Control group

    Nursing homes in the control group will not receive the ORANEAT antibiotic stewardship program ("usual care").

Interventions

  • OtherThe ORANEAT program

    The ORANEAT multifaceted customizable antibiotic stewardship program includes (i) a contextual diagnostic regarding AMS in the targeted NH; (ii) based on the results of the contextual diagnostic, a bundle of tools selected from an AMS-toolkit including actions and tools suited to French NH setting and covering the main CDC domains of AMS in NHs; and (iii) implementation support relying on French structures involved in tackling AMR (i.e., CRAtb and CPias).

06

What researchers measure

Primary outcomes

  1. Overall antibiotic prescription rate (DDD)

    Overall antibiotic prescription rate expressed in Defined Daily Doses (DDD)/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.

    Time frame: 12 months

  2. Overall antibiotic prescription rate (number of prescriptions)

    As part of a sensitivity analysis: Overall antibiotic prescription rate expressed in number of prescriptions/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.

    Time frame: 12 months

Secondary outcomes

  1. Effectiveness of the intervention - broad-spectrum antibiotics

    Broad-spectrum antibiotic prescription rate expressed in Defined Daily Doses (DDD)/1000 resident-days/month. Broad-spectrum antibiotics include quinolones and 3rd-generation cephalosporins. Measured using data from the Health Insurance reimbursement database.

    Time frame: 12 months

  2. Effectiveness of the intervention - appropriateness of antibiotic prescriptions

    Proxy indicators reflecting the appropriateness of antibiotic use in nursing homes (Asquier-Khati et al. 2023, doi:10.1093/jacamr/dlad037). These proxy indicators assess the appropriateness of prescriptions for urinary tract infections, seasonal variations in prescriptions, repeated prescriptions of fluoroquinolones, cephalosporins' route of administration, duration of treatment, rate of second-line antibiotics, and co-prescriptions with non-steroidal anti-inflammatory drugs.

    Time frame: 12 months

  3. Safety of the intervention

    Number of hospital admissions/1000 resident-days and number of deaths/1000 resident-days among nusing home residents. Measured using data from the Health Insurance reimbursement database.

    Time frame: 12 months

  4. Sustainability of the effectiveness

    Overall antibiotic prescription rate expressed in Defined Daily Doses (DDD)/1000 resident-days/month. As part of a sensitivity analysis: Overall antibiotic prescription rate expressed in number of prescriptions/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.

    Time frame: 24 months

Other outcomes

  1. Context of the intervention - nursing homes' characteristics

    Nursing homes' staff resources (number of coordinating physicians, nurses, assistant nurses and general practitioners). Measured using data collected by the research team through ad hoc standardized activity reports.

    Time frame: At inclusion

  2. Context of the intervention - nursing homes' geographic areas' characteristics

    Characteristics of the geographic areas of the nursing homes (type of area: rural/semi-urban/urban; access to general practioners in the area according to the Local Potential Accessibility Index, which considers the number of general practioners, their level of activity, the age of the population, and the distance to GPs' offices within the municipality ). Measured using data from administrative public databases.

    Time frame: At inclusion

  3. Adoption of the intervention

    Number of nursing homes included / number of nursing homes invited to participate in the intervention group \* 100, by stratum. Measured using data collected by the research team through ad hoc standardized activity reports.

    Time frame: 12 months

  4. Reach of the target population - contextual diagnosis

    For each profesionnal category (nursing home coordinating physician or nurse, nurses, assistant nurses and referring general practitioners), participation rate (%) in the contextual diagnostic questionnaire of the ORANEAT program (first component of the program), calculated as as the number of completed questionnaires divided by the total number of professionals in that category x 100.

    Time frame: 12 months

  5. Reach of the target population - antimicrobial stewardship tools/actions

    Proportion of nurses and assistant nurses attending at least one training session; proportion of referring general practitioners contacted at least once regarding the ORANEAT program by the external or the internal facilitators; number of tools distributed (number of copies provided to the nursing home, for each tool); proportion of nursing homes that developed at least one tool as part of the "tool development" action of the ORANEAT program. Measured using data collected by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  6. Fidelity of the intervention - antimicrobial stewardship tools

    Number of tools used / number of tools included in the bundle of tools, for each bundle. Measured using data collected by the by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  7. Fidelity of the intervention - categories of antimicrobial stewardship tools

    Number of categories of the antimicrobial stewardship tools/actions implemented in the nursing home according to the contextual diagnostic tool of the ORANEAT program and their evolution over 12 months. Categories are defined according to the Centers for Disease Control and Prevention (CDC) core elements of antibiotic stewardship for nursing homes. Data collected through the questionnaires of the contextual diagnostic.

    Time frame: At 3 months, 6 months, 9 months and 12 months

  8. Dose of intervention - score of exposure to the intervention

    Score of exposure to each component of the ORANEAT program. This composite measure will capture the intensity of exposition to each component of the program in each nursing home (i.e., the contextual diagnosis, the exposition to the tools/actions, and the implementation strategies). Measured using data collected by the research team through ad hoc standardized activity reports, the questionnaires of the contextual diagnostic and annual activity reports from the local antimicrobial stewardship teams.

    Time frame: Through the end of the intervention, an average of 12 months

  9. Dose of intervention - antimicrobial stewardship tools

    Number of tools used for each target population. Measured using data collected by the by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  10. Dose of intervention - implementation support

    Number of meetings with the internal and external facilitators held as part of the implementation support of the ORANEAT program (third component of the program). Measured using data collected by the by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  11. Dose of intervention - time to implement the program

    Average time (days) between validation of the pack with the internal facilitators and the date when all tools are reported as used. Measured using data collected by the by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  12. Adaptation of the intervention

    Number of tools withdrawn from the bundle of tools or modified (in form and/or content) or added / number of tools initially proposed (for each bundle of tools and overall). Measured using data collected by the by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  13. Users' experiences of the intervention

    Users' experiences with the ORANEAT program assessed among coordinating physicians/nurses, nurses, assistant nurses and general practitioners using a questionnaire UREMs (User Reported Experience Measures) adapted from PREMs (Patient Reported Experience Measures) developed by the research team. This questionnaire was designed to measure the users reported experience of the intervention. A score ranging from 0 to 100 will be calculated; higher score means better experience.

    Time frame: 12 months

  14. Sustainability of the intervention

    Sustainability of the ORANEAT program assessed among coordinating physicians/nurses, nurses, assistant nurses and general practitioners using the NoMAD questionnaire (questionnaire based on the normalization process theory \[NPT\], measuring the normalization of complex healthcare interventions - Finch et al. 2018 - doi: 10.1186/s12874-018-0591-x). The NoMAD questionnaire includes three general items on the intervention answered on an 11-point Likert scale ranging from 0 to 10, and 20 items representing the four key constructs of NPT: coherence (4 items), cognitive participation (4 items), collective action (7 items), and reflexive monitoring (5 items) answered on a 5-point Likert scale ranging from strongly agree to strongly disagree. Mean scale scores will be calculated for each NoMAD construct as well as for the overall scale (20 items); higher scores mean higher degree of normalization.

    Time frame: 12 months

  15. Mechanisms of impact of the intervention - prescriptions of urine cultures

    Number of urine cultures prescribed/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.

    Time frame: 12 months

  16. Mechanisms of impact of the intervention - nursing home professionals' knowledge, attitudes, practices and motivation

    Nursing home professionals' (coordinating physicians/nurses, nurses, assistant nurses and general practitioners) knowledge, attitudes, practices and motivation towards AMS. For each component (knowledge, attitudes, practices and motivation), a score ranging from 0 to 100 will be calculated; higher scores means more favorable position towards AMS. Data collected through the questionnaires of the contextual diagnostic.

    Time frame: At inclusion, 6 and 12 months

  17. Costs of the intervention

    Cost associated with the work provided by the professionals responsible for the implementation support, with printing and sending the ORANEAT program tools to the nursing homes, etc. Measured using data collected by the by the research team through ad hoc standardized activity reports.

    Time frame: Through the end of the intervention, an average of 12 months

  18. Context, mechanisms of impact, sustainability, implementation, and transferability of the intervention

    Observations, semi-structured interviews, focus groups with professionals involved in the implementation of the ORANEAT program (coordinating physicians/nurses, nurses, assistant nurses, general practitioners, professionals responsible for the implementation support…).

    Time frame: Through the end of the intervention, an average of 12 months

07

Study locations

2 of 2 sites recruiting
  • CPias PdL (for the Pays de la Loire region)
    Nantes, 44093, France
    Recruiting
  • CIC-EC (for the Grand Est region)
    Vandœuvre-lès-Nancy, 54505, France
    Recruiting
08

References and documents

Publications

  • Gonthier D, Ricci L, Buzzi M, Birgand G, Kivits J, Agrinier N. Exploration of interprofessional collaboration for the diagnosis of infections and antibiotic prescription in nursing homes using multiple case study observational research. JAC Antimicrob Resist. 2025 Jan 13;7(1):dlae205. doi: 10.1093/jacamr/dlae205. eCollection 2025 Feb. PubMed 39807109 ↗
  • Bocquier A, Erkilic B, Babinet M, Pulcini C, Agrinier N; ORANEAT Study Group. Resident-, prescriber-, and facility-level factors associated with antibiotic use in long-term care facilities: a systematic review of quantitative studies. Antimicrob Resist Infect Control. 2024 Mar 6;13(1):29. doi: 10.1186/s13756-024-01385-6. PubMed 38448955 ↗
  • Conlin M, Hamard M, Agrinier N, Birgand G; ORANEAT co-investigators. Assessment of implementation strategies adopted for antimicrobial stewardship interventions in long-term care facilities: a systematic review. Clin Microbiol Infect. 2024 Apr;30(4):431-444. doi: 10.1016/j.cmi.2023.12.020. Epub 2023 Dec 22. PubMed 38141820 ↗

Individual participant data

Plan to share: No — IPD Sharing Plan Description: N/A

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Dec 2025 → Apr 2026, primary completion Jan 2027 → Jul 2027 and completion Jan 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Nov 24, 2025
StartActual
Apr 14, 2026was Dec 2025
Primary completionEst.
Jul 14, 2027was Jan 2027
CompletionEst.
Jul 14, 2028was Jan 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
2 sites added — first site in France
Show 2 added (2 France)
  • CPias PdL (for the Pays de la Loire region) · Nantes, France
  • CIC-EC (for the Grand Est region) · Vandœuvre-lès-Nancy, France
Oct 5, 2026
Start date
Dec 15, 2025→Apr 14, 2026 (actual)
Oct 5, 2026
Primary completion
Jan 30, 2027→Jul 14, 2027
Oct 5, 2026
Study completion
Jan 30, 2028→Jul 14, 2028
Oct 5, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedTotalOverall antibiotic useprescription rate (DDD)Time frame: 12 months
  • EditedTotalOverall antibiotic useprescription rate (Numbernumber of prescriptions)Time frame: 12 months
Oct 5, 2026
Secondary outcomes
4 edited, 8 added, 1 removed, 1 description edited
What changed in the outcomes
  • AddedEffectiveness of the intervention - broad-spectrum antibioticsTime frame: 12 months
  • AddedEffectiveness of the intervention - appropriateness of antibiotic prescriptionsTime frame: 12 months
  • DescriptionSustainability of the effectiveness: how it is measured was reworded
  • Editedother outcomeContext of the intervention - Nursingnursing homes' characteristicsTime frame: At inclusion
  • Editedother outcomeReach of the target population - contextual diagnosisTime frame: Through the end of the intervention, an average of 12 months → 12 months
  • Editedother outcomeFidelity of the intervention - antimicrobial stewardship toolsTime frame: Through the end of the intervention, an average of 12 months
  • Editedother outcomeDose of intervention - antimicrobial stewardship toolsTime frame: Through the end of the intervention, an average of 12 months
  • Addedother outcomeContext of the intervention - nursing homes' geographic areas' characteristicsTime frame: At inclusion
  • Addedother outcomeReach of the target population - antimicrobial stewardship tools/actionsTime frame: Through the end of the intervention, an average of 12 months
  • Addedother outcomeFidelity of the intervention - categories of antimicrobial stewardship toolsTime frame: At 3 months, 6 months, 9 months and 12 months
  • Addedother outcomeDose of intervention - score of exposure to the interventionTime frame: Through the end of the intervention, an average of 12 months
  • Addedother outcomeDose of intervention - implementation supportTime frame: Through the end of the intervention, an average of 12 months
  • Addedother outcomeDose of intervention - time to implement the programTime frame: Through the end of the intervention, an average of 12 months
  • Removedother outcomeMechanisms of impact of the intervention - appropriateness of antibiotic prescriptionsTime frame: 12 months
Oct 5, 2026
Contact
Study contact changed: a•••@chru-nancy.fr · •••3530→M•••@chru-nancy.fr · •••3479; •••6292→•••6292. See the current contact
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in France
    Show 2 added (2 France)
    • CPias PdL (for the Pays de la Loire region) · Nantes, France
    • CIC-EC (for the Grand Est region) · Vandœuvre-lès-Nancy, France
    Start date Dec 15, 2025→Apr 14, 2026 (now actual)
    Primary completion Jan 30, 2027→Jul 14, 2027
    Study completion Jan 30, 2028→Jul 14, 2028
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedTotalOverall antibiotic useprescription rate (DDD)Time frame: 12 months
    • EditedTotalOverall antibiotic useprescription rate (Numbernumber of prescriptions)Time frame: 12 months
    Secondary outcomes 4 edited, 8 added, 1 removed, 1 description edited
    What changed in the outcomes
    • AddedEffectiveness of the intervention - broad-spectrum antibioticsTime frame: 12 months
    • AddedEffectiveness of the intervention - appropriateness of antibiotic prescriptionsTime frame: 12 months
    • DescriptionSustainability of the effectiveness: how it is measured was reworded
    • Editedother outcomeContext of the intervention - Nursingnursing homes' characteristicsTime frame: At inclusion
    • Editedother outcomeReach of the target population - contextual diagnosisTime frame: Through the end of the intervention, an average of 12 months → 12 months
    • Editedother outcomeFidelity of the intervention - antimicrobial stewardship toolsTime frame: Through the end of the intervention, an average of 12 months
    • Editedother outcomeDose of intervention - antimicrobial stewardship toolsTime frame: Through the end of the intervention, an average of 12 months
    • Addedother outcomeContext of the intervention - nursing homes' geographic areas' characteristicsTime frame: At inclusion
    • Addedother outcomeReach of the target population - antimicrobial stewardship tools/actionsTime frame: Through the end of the intervention, an average of 12 months
    • Addedother outcomeFidelity of the intervention - categories of antimicrobial stewardship toolsTime frame: At 3 months, 6 months, 9 months and 12 months
    • Addedother outcomeDose of intervention - score of exposure to the interventionTime frame: Through the end of the intervention, an average of 12 months
    • Addedother outcomeDose of intervention - implementation supportTime frame: Through the end of the intervention, an average of 12 months
    • Addedother outcomeDose of intervention - time to implement the programTime frame: Through the end of the intervention, an average of 12 months
    • Removedother outcomeMechanisms of impact of the intervention - appropriateness of antibiotic prescriptionsTime frame: 12 months
    Contact Study contact changed: a•••@chru-nancy.fr · •••3530→M•••@chru-nancy.fr · •••3479; •••6292→•••6292. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07246382
Lead sponsor
University of Lorraine
Collaborators
Sciences Po, Centre de Sociologie des Organisations (CSO), CNRS, Paris, France., Inserm U1219, Bordeaux Population Health Research Center, Bordeaux, France., Centre Régional en Antibiothérapie (CRAtb) Grand Est, Nancy, France., Centre Régional en Antibiothérapie (CRAtb) Pays de la Loire, Nantes, France., National Research Agency, France, Centre d'appui pour la Prévention des Infections Associées aux Soins (CPias) Pays de la Loire, Nantes, France., Centre d'appui pour la Prévention des Infections Associées aux Soins (CPias) Grand Est, Nancy, France.
Responsible party
Nelly Agriner (Professor, University of Lorraine) — Principal investigator
First posted
Nov 24, 2025
Start date
Apr 14, 2026
Primary completion
Jul 14, 2027 (estimated)
Completion
Jul 14, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Mélanie BEGUINET
Contact
M.BEGUINET@chru-nancy.fr
+333 83 15 34 79
Aurélie BOCQUIER
Contact
Aurelie.bocquier@univ-lorraine.fr
+33372746292
Nelly AGRINIER, Professor
principal investigator · Université de Lorraine, Inserm, INSPIIRE, F-54000 Nancy, France; CHRU-Nancy, Inserm, Université de Lorraine, CIC, Epidémiologie clinique, Nancy, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion